Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > Octoplus and Cytimmune give anticancer drug TNF new chance

May 28th, 2003

Octoplus and Cytimmune give anticancer drug TNF new chance

Abstract:
OctoPlus and CytImmune Sciences, Inc., announced today that they have entered into a collaboration agreement to develop a novel treatment for solid cancers. The treatment's active agent is the anticancer protein, tumor necrosis factor (TNF). (see 2nd story)

Source:
Octoplus

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books



NNN
The Hunger Project